PHA 301: Comprehensive Study Notes - Introductory Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/24

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary study cards covering basic pharmacology concepts, pharmacokinetics (ADME), biotransformation, hepatobiliary and renal excretion, quantitative clearance and half-life kinetics, and fundamental pharmacodynamics.

25 Terms

1
New cards

Pharmacokinetics

The study of what the body does to a drug, tracking its movement through the body via absorption, distribution, metabolism, and excretion (ADME).

2
New cards

Pharmacodynamics

The study of what a drug does to the body, encompassing biochemical and physiological mechanisms, receptor binding, and dose-response relationships.

3
New cards

Therapeutic Index (TI\text{TI})

A quantitative ratio reflecting drug safety, determined by comparing toxic or lethal dose to effective dose: TI=TD<em>50ED</em>50\text{TI} = \frac{\text{TD}<em>{50}}{\text{ED}</em>{50}}

4
New cards

Intravenous route of administration

The route that injects a compound directly into the vascular compartment, completely bypassing absorption to achieve 100%100\% bioavailability.

5
New cards

pH-partition hypothesis

The principle stating that weak acids remain predominantly un-ionized and lipid-permeable in acidic media, whereas weak bases remain un-ionized in alkaline environments.

6
New cards

Small intestine

The principal anatomical site of oral drug absorption for both weak acids and weak bases, driven by extensive mucosal surface area and high blood flow.

7
New cards

First-pass metabolism

The presystemic hepatic clearance of an orally administered drug absorbed from the gastrointestinal tract into the portal vein before reaching systemic circulation.

8
New cards

Bioavailability (FF)

The fraction or percentage of an administered drug dose that successfully enters systemic circulation in an unchanged chemical state.

9
New cards

Apparent volume of distribution (VdV_d)

A theoretical proportionality constant relating the total amount of drug present in the body to its concentration in plasma: V<em>d=Amount of drugC</em>pV<em>d = \frac{\text{Amount of drug}}{\text{C}</em>p}

10
New cards

Free drug fraction

The unbound portion of circulating drug capable of diffusing across biological membranes, interacting with receptors, and undergoing metabolic and renal clearance.

11
New cards

Phase I drug metabolism

Non-synthetic functionalization reactions—principally oxidation, reduction, and hydrolysis catalyzed by Cytochrome P450 enzymes—that introduce or unmask polar chemical groups.

12
New cards

Phase II drug metabolism

Synthetic conjugation reactions that link parent drugs or Phase I products to endogenous polar moieties (such as glucuronic acid or glutathione) to form excretable hydrophilic conjugates.

13
New cards

Enzyme induction

The enhanced expression and catalytic capacity of hepatic microsomal enzymes triggered by specific agents, leading to accelerated metabolism and reduced efficacy of co-administered drugs.

14
New cards

Enzyme inhibition

The reduction in catalytic activity of drug-metabolizing enzymes by a competing compound, leading to reduced clearance and potential toxicity of co-administered drugs.

15
New cards

Probenecid interaction with Penicillin

Competitive inhibition of organic anion transporters (OATs) in the proximal renal tubule, reducing renal tubular secretion and prolonging the antibiotic's half-life.

16
New cards

Urinary alkalinization

The therapeutic infusion of sodium bicarbonate to ionize weak acids in renal tubules, trapping them in urine to accelerate elimination during an overdose.

17
New cards

Enterohepatic circulation

The biliary excretion of glucuronide conjugates followed by bacterial β\beta-glucuronidase hydrolysis in the bowel, which liberates free lipophilic drug for intestinal reabsorption.

18
New cards

Drug clearance (CL\text{CL})

The theoretical volume of plasma completely cleared of a drug per unit of time across eliminating organs: CL=k<em>e×V</em>d\text{CL} = k<em>e \times V</em>d

19
New cards

Elimination half-life (t1/2t_{1/2})

The duration required for plasma drug concentration to decrease by half during the post-absorptive elimination phase: t<em>1/2=0.693×V</em>dCLt<em>{1/2} = \frac{0.693 \times V</em>d}{\text{CL}}

20
New cards

First-order kinetics

A linear elimination pattern in which a constant fraction of drug is eliminated per unit of time, keeping clearance and half-life independent of drug concentration.

21
New cards

Zero-order kinetics

A nonlinear elimination pattern where a constant absolute amount of drug is cleared per unit of time because metabolizing enzymes or transport mechanisms are fully saturated.

22
New cards

Steady state (Css\text{C}_{ss})

The dynamic equilibrium achieved during continuous or repeated dosing when drug administration rate equals elimination rate, typically requiring 4 to 5 half-lives.

23
New cards

Loading dose (LD\text{LD})

A large initial dose calculated using volume of distribution (VdV_d) to achieve therapeutic plasma levels rapidly without waiting for steady state to accumulate over multiple half-lives.

24
New cards

Competitive antagonist

A ligand that reversibly binds the agonist's receptor site, shifting the concentration-response curve to the right without reducing maximal response (Emax⁡E_{\max}).

25
New cards

Non-competitive antagonist

An agent that binds allosterically or irreversibly to a receptor, depressing the maximal achievable response (Emax⁡E_{\max}) regardless of how much agonist is added.